View:
Download DOC
Download PDF
Download XLS
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Perrin Steven
(Last) (First) (Middle)
C/O NOVUS THERAPEUTICS, INC.
19900 MACARTHUR BLVD., SUITE 550
(Street)
IRVINE CA 92612
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/14/2020 		3. Issuer Name and Ticker or Trading Symbol
Novus Therapeutics, Inc. [ NVUS ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1) 09/14/2030 Series X1 Convertible Preferred Stock(2) 7,856.409 500 D
Stock Option (Right to Buy) (3) 01/28/2030 Series X1 Convertible Preferred Stock(2) 2,078.859 495 D
Stock Option (Right to Buy) (3) 01/28/2030 Common Stock 48,896 0.495 D
Stock Option (Right to Buy) (3) 01/28/2030 Series X1 Convertible Preferred Stock(2) 2,514.285 495 D
Stock Option (Right to Buy) (3) 01/28/2030 Common Stock 56,719 0.495 D
Stock Option (Right to Buy) (3) 09/07/2030 Series X1 Convertible Preferred Stock(2) 10,672.926 380.8 D
Stock Option (Right to Buy) (3) 09/07/2030 Common Stock 240,767 0.3808 D
Stock Option (Right to Buy) (4) 01/28/2030 Series X1 Convertible Preferred Stock(2) 432.257 495 D
Stock Option (Right to Buy) (4) 01/28/2030 Common Stock 9,751 0.495 D
Stock Option (Right to Buy) (4) 01/28/2030 Series X1 Convertible Preferred Stock(2) 656.165 495 D
Stock Option (Right to Buy) (4) 01/28/2030 Common Stock 14,802 0.495 D
Explanation of Responses:
1. This option represents a right to purchase a total of 7,856.409 shares of the Issuer's Series X1 Convertible Preferred Stock, with 1,949.260 shares vesting in equal monthly installments over a period of one year from the grant date, and with the remaining 5,907.149 shares vesting over a period of two years from the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.
2. Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.
3. The option vests in equal monthly installments over a period of four years from January 1, 2019, the vesting start date.
4. The option is fully vested.
Remarks:
President and Chief Scientific Officer Ex. 24 - Power of Attorney
/s/ Ryan A. Murr, as attorney-in-fact for Steven Perrin 09/24/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                               POWER OF ATTORNEY

    Know all by these presents, that the undersigned hereby constitutes and
appoints Jon Kuwahara and Ryan A. Murr, with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:

    (1) prepare, execute in the undersigned's name and on the undersigned's
        behalf, and submit to the U.S. Securities and Exchange Commission (the
        "SEC") a Form ID, including amendments thereto, and any other documents
        necessary or appropriate to obtain codes, passwords and passphrases
        enabling the undersigned to make electronic filings with the SEC of
        reports required by the Securities Exchange Act of 1934 or any rule or
        regulation of the SEC;

    (2) execute for and on behalf of the undersigned, in the undersigned's
        capacity as an officer and/or director of Novus Therapeutics, Inc. (the
        "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the
        Securities Exchange Act of 1934 and the rules thereunder;

    (3) do and perform any and all acts for and on behalf of the undersigned
        which may be necessary or desirable to complete and execute any such
        Form 3, 4, or 5, complete and execute any amendment or amendments
        thereto, and timely file such form with the SEC and any securities
        exchange or similar authority; and

    (4) take any other action of any type whatsoever in connection with the
        foregoing which, in the opinion of such attorney-in-fact, may be of
        benefit to, in the best interest of, or legally required by, the
        undersigned, it being understood that the documents executed by such
        attorney-in-fact on behalf of the undersigned pursuant to this Power of
        Attorney shall be in such form and shall contain such terms and
        conditions as such attorney-in-fact may approve in such attorney-in-
        fact's discretion.

    The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned also ratifies hereby any action previously taken by
each attorney-in-fact that would have been authorized by this power of attorney
if it has been in effect at the time such action was taken. The undersigned
acknowledges that the foregoing attorney-in-fact, in serving in such capacity at
the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934, as amended.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 16th day of September 2020.



                                         /s/ Steven Perrin
                                         --------------------
                                         Signature

                                         Steven Perrin
                                         --------------------
                                         Print Name